PARP inhibitors in the ovarian cancer therapy

被引：0

作者：

Kruczala, Maksymilian A. ^{[1
]}

Grela-Wojewoda, Aleksandra ^{[1
]}

Cedrych, Ida ^{[1
]}

机构：

[1] Klin Nowotworow Ukladowych & Uogolnionych, Ctr Onkol Inst, Marii Sklodowskiej Curie Oddzial Krakowie, Ul Garncarska 11, PL-31115 Krakow, Poland

来源：

GINEKOLOGIA POLSKA | 2016年 / 87卷 / 02期

关键词：

targeted therapy; ovarian cancer; PARP inhibitors; RANDOMIZED PHASE-2; OLAPARIB; TRIAL;

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Treatment of the malignant ovarian tumors remains a considerable challenge due to various reasons, including lack of effective screening technique, usually asymptomatic early stages of the disease, resulting in advanced stages of the disease at diagnosis, and eventually poor prognosis. Treatment of the relapse remains palliative. New drugs like PARP inhibitors - offer hope for the improvement of treatment outcomes. This review paper presents the current state of knowledge on PARP inhibitors in ovarian cancer therapy.

引用

页码：131 / 134

页数：4

共 13 条

[1]

[Anonymous], 2008, J NATL CANC I, V95, P1331

[2]

[Anonymous], 2009, NOWOTWORY ZLOSLIWE P

[3] Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial [J].

Buys, SS ;

Partridge, E ;

Greene, MH ;

Prorok, PC ;

Reding, D ;

Riley, TL ;

Hartge, P ;

Fagerstrom, RM ;

Chia, D ;

Izmirlian, G ;

Fouad, M ;

Ragard, LR ;

Johnson, CC ;

Gohagan, JK .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (05) :1630-1639

[4] Development of an ovarian cancer symptom index - Possibilities for earlier detection [J].

Goff, Barbara A. ;

Mandel, Lynn S. ;

Drescher, Charles W. ;

Urban, Nicole ;

Gough, Shirley ;

Schurman, Kristi M. ;

Patras, Joshua ;

Mahony, Barry S. ;

Andersen, M. Robyn .

CANCER, 2007, 109 (02) :221-227

[5]

Janas L, 2015, GINEKOL POL, V86, P193

[6] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].

Kaufman, Bella ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Steiner, Mariana ;

Loman, Niklas ;

Bowen, Karin ;

Fielding, Anitra ;

Domchek, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250

[7] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare L. ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Fielding, Anitra ;

Spencer, Stuart ;

Dougherty, Brian ;

Orr, Maria ;

Hodgson, Darren ;

Barrett, J. Carl ;

Matulonis, Ursula .

LANCET ONCOLOGY, 2014, 15 (08) :852-861

[8] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J].

Liu, Joyce F. ;

Barry, William T. ;

Birrer, Michael ;

Lee, Jung-Min ;

Buckanovich, Ronald J. ;

Fleming, Gini F. ;

Rimel, B. J. ;

Buss, Mary K. ;

Nattam, Sreenivasa ;

Hurteau, Jean ;

Luo, Weixiu ;

Quy, Philippa ;

Whalen, Christin ;

Obermayer, Lisa ;

Lee, Hang ;

Winer, Eric P. ;

Kohn, Elise C. ;

Ivy, S. Percy ;

Matulonis, Ursula A. .

LANCET ONCOLOGY, 2014, 15 (11) :1207-1214

[9] Targeted therapy for cancer using PARP inhibitors [J].

Lord, Christopher J. ;

Ashworth, Alan .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) :363-369

[10]

Lynparza, CHAR PROD LECZN

← 1 2 →